EVs have shown extensive application prospects in tumor therapy.[27] Engineered EVs, which are essential carriers for tumor therapy, have shown satisfactory efficacy in treating a variety of tumors.[28] This study showed that CD109+ EVs exhibited strong neuro‐targeting potential and are expected to constitute a breakthrough in the development of targeted therapies for neuroinvasive PDAC. Here, CD109 is linked to neoplasm.